Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroVasx completes $8.5 million private placement
The company also reported completion of long-term follow-up on 20 patients treated with the cPAX Aneurysm treatment system in a clinical study which was completed in May. Eric
The company also reported completion of long-term follow-up on 20 patients treated with the cPAX Aneurysm treatment system in a clinical study which was completed in May. Eric
Bard’s peripheral vascular division, located in Tempe, Arizona, will assume marketing responsibility for the product. The company expects to close the transaction following the satisfaction of customary conditions,
In order to optimize its selling effort, Trinity Biotech has decided to reorganize its sales and marketing function into two divisions, the clinical laboratory division and the point-of-care
The collaboration will explore the novel signaling pathways targeted by two of Jerini Ophthalmic’s leading drug candidates, JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of
The company said that AVN944 biomarkers show a dose-dependent increase in activity including, binding to the target enzyme IMPDH, depletion of GTP pools in blast cells and gene
The median overall survival advantage for Vidaza-treated patients compared to conventional care regimens (CCR) treated patients in this clinical trial in myelodysplastic syndromes (MDS) was 9.4 months (24.4
To date, 33 patients have been enrolled in this ongoing open-label Phase II study of refractory/relapsed classical Hodgkin lymphoma (HL). The majority of these patients have disease that
Additionally, romiplostim-treated patients taking concurrent immune thrombocytopenic purpura (ITP) medications such as corticosteroids were able to reduce or discontinue these medications. Efficacy and safety data from another pivotal
Revlimid was active with both dose levels of dexamethasone. The best overall response for high-dose dexamethasone (CR/VGPR/PR) was 82% compared to 71% in the low-dose dexamethasone arm, including
The company said that it has changed its corporate name to emphasize its mission to commercialize the mammastatin serum assay and to pursue development of the mammastatin protein